Investing.com - Fresh Tracks Therapeutics (NASDAQ: FRTX) reported third quarter EPS of $0.3200, $0.92 better than the analyst estimate of $-0.6000. Revenue for the quarter came in at $7.94M versus the consensus estimate of $4.5M.
Fresh Tracks Therapeutics's stock price closed at $0.9300. It is up 46.5300% in the last 3 months and down -54.5000% in the last 12 months.
Fresh Tracks Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Fresh Tracks Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Fresh Tracks Therapeutics's Financial Health score is "fair performance".
Check out Fresh Tracks Therapeutics's recent earnings performance, and Fresh Tracks Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar